- On sale!
- On sale!
The components of Ricovir-EM (Truvada) are emtricitabine (200mg) and tenofovir disoproxil fumarate (300mg) TDF. These are the active ingredients used in HIV-negative people. This type of regimen with Ricovir EM is known as PrEP (pre-exposure prophylaxis), and is almost entirely successful in preventing HIV infection.
In terms of adverse consequences of using Ricovir EM, only a very small group of people have reported symptoms such as nausea, malaise, fever or skin rashes, which disappear immediately when PREP treatment is stopped. Pre-exposure prophylaxis treatment can be started and stopped in any situation and without the need for a pattern. For HIV-positive people, more specific medication is available and should be used instead of Ricovir or any other PrEP.
You might also like
Ricovir EM are Emtricitabine (200mg) / Tenofovir disoproxil fumarate (300mg) TDF (Truvada) is used as PrEP (pre-exposure prophylaxis) in HIV (human immunodeficiency virus) negative people and is almost entirely successful in preventing HIV infection.
From a health point of view, Ricovir-EM is recommended for all people who are sexually active, which means that they are at an increased risk of contracting HIV.
This preventive treatment is not only essential because it prevents us from becoming infected with HIV as individuals, but it is predicted that over time it will play a decisive role in defeating the disease for good.
This drug, which belongs to the so-called antiretroviral drugs, works by interfering with the normal work of an enzyme that is essential for the virus to reproduce. Thus, buying RICOVIR EM is undoubtedly a good decision, as those who take it correctly see their chances of contracting HIV reduced by up to 99%, making it a perfect option for protection against this infection and with the support of the WHO at a global level, and the FDA (Food and Drug Administration) and the AEMPS (Spanish Agency for Medicines and Health Products). Mylan is the prestigious pharmaceutical company that markets this medicine.
The first study to corroborate the success of PrEP for HIV prevention (iPrex study) was conducted in 2010. People were given a combination of emtricitabine and tenofovir disoproxil furamate (FTC/TDF), the main components of PrEP. Since then, studies on the efficacy of PrEP in the fight to prevent HIV infection have been ongoing and increasingly successful.
Even if treatment with Ricovir prep is successful in preventing HIV, it does not provide protection against other STDs, which is why it should be combined with the use of condoms.
It should be borne in mind that this form of pre-exposure prophylaxis (PrEP) should not be an option for people who are HIV-positive, as there are suitable treatments for them that do not generate resistance in the virus. It is therefore important to know your HIV status before starting PrEP treatment, as well as your vaccination status for other sexually transmitted infections.